UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

  For Period Ended: September 30, 2021
   
  ☐ Transition Report on Form 10-K
   
  ☐ Transition Report on Form 20-F
   
  ☐ Transition Report on Form 11-K
   
  ☐ Transition Report on Form 10-Q
   
  ☐ Transition Report on Form N-SAR
   
  For the Transition Period Ended: ______________________

 

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _________________________________

 

PART I - REGISTRANT INFORMATION

 

MusclePharm Corporation
Full Name of Registrant
 
 
Former Name if Applicable
 
3753 Howard Hughes Parkway, Ste 200-849
Address of Principal Executive Office (Street and Number)
 
Las Vegas, NV 89169
City, State and Zip Code

 

 

 

 

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25 has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Company was unable to compile the necessary financial information required to prepare a complete filing, in part due to the Company’s transition to a new Chief Financial Officer and turnover within the Company’s accounting department. Thus, the Company would be unable to file the quarterly report in a timely manner without unreasonable effort or expense. The Company expects to file the quarterly report within the extension period.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of the person to contact in regard to this notification

 

Sabina Rizvi   (800)   292-3909
(Name)   (Area Code)   (Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

☒ Yes ☐ No

   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

MusclePharm Corporation

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 15, 2021 By: /s/ Sabina Rizvi
    Sabina Rizvi
    President and Chief Financial Officer

 

 

 

 

Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Muscle Pharm (CE) Charts.
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Muscle Pharm (CE) Charts.